| 引用本文： |
-
周乐,曹华明,陆瑾玥,等.达格列净对Ⅱ型心肾综合征患者心肾功能及短期预后的影响[J].同济大学学报（医学版）,2023,44(2):246-251. [点击复制]
- ZHOU Le,CAO Huaming,LU Jinyue,et al.Effect of dapagliflozin on cardiac and renal function and short-term prognosis in patients with type 2 cardiorenal syndrome[J].同济大学学报（医学版）,2023,44(2):246-251. [点击复制]
|
|
| 摘要: |
| 目的观察在常规治疗基础上，加用达格列净对Ⅱ型心肾综合征(cardiorenal syndrome, CRS)患者的血清肌酐(serum creatinine, SCr)、血胱抑素C(cystatin C, Cys-C)、可溶性生长激素表达基因2蛋白(growth stimulation expressed gene 2, sST2)和N末端B型利钠肽原(n-terminal pro b-type natriuretic peptide, NT-proBNP)的影响。方法选取Ⅱ型CRS患者94例，随机分为对照组48例(常规治疗)和观察组46例(常规治疗的基础上加用达格列净10 mg)，在基线与治疗24周后检测心肾功能指标，并观察短期预后以及不良反应。结果与对照组比较，观察组患者的SCr、Cys-C、sST2和NT-proBNP值均明显降低(P＜0.05)，观察组主要不良心血管事件发生率更低(P＜0.05)。结论在常规治疗基础上加用达格列净10 mg可显著降低Ⅱ型CRS患者的SCr、Cys-C、sST2和NT-proBNP水平及改善短期预后，且sST2可用来判断Ⅱ型CRS患者心肾功能，有助于指导诊疗。 |
| 关键词: 达格列净 Ⅱ型心肾综合征 血清肌酐 血胱抑素C 可溶性生长激素表达基因2蛋白 N末端B型利钠肽原 |
| DOI：10.12289/j.issn.1008-0392.22494 |
| 投稿时间：2022-12-21 |
| 基金项目:上海市静安区学科建设资助项目(2021PY03)；上海市静安区市北医院科研课题(面上2022SBMS02) |
|
| Effect of dapagliflozin on cardiac and renal function and short-term prognosis in patients with type 2 cardiorenal syndrome |
| ZHOU Le,CAO Huaming,LU Jinyue,GENG Xiaohong,CHEN Yi,HU Yi |
| (Department of Cardiology, Shibei Hospital of Jing’an District, Shanghai 200435, China) |
| Abstract: |
| ObjectiveTo investigate the effect of dapagliflozin on cardiac and renal function and short-term prognosis in patients with type 2 cardiorenal syndrome(CRS). MethodsA total of 94 patients with type 2 CRS were randomly divided into two groups. Patients in control group(n=48) received conventional therapy, and patients in the study group(n=46) were given dapagliflozin tablets 10 mg qd on the basis of conventional therapy for 24 consecutive weeks. The clinical efficacy, and the indexes of cardiac and renal function were compared between two groups; the short-term outcome and adverse events were observed. ResultsThe serum creatinine(SCr), cystatin C(cysC), growth stimulation expressed gene 2(sST2) and N-terminal pro B-type natriuretic peptide(NT-proBNP) levels in study group were significantly lower than those in the control group(all P<0.05). And the incidence of major adverse cardiovascular events in the study group was significantly lower than that in the control group(P<0.05). ConclusionDapagliflozin can reduce serum SCr, CysC, sST2 and NT-proBNP levels in patients with type 2 CRS and improve short-term prognosis. |
| Key words: dapagliflozin type 2 cardiorenal syndrome serum creatine cystatin C growth stimulation expressed gene 2 NT-proBNP |
